Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564800 | 0.83 | MAOA (0.45) | KMT2AMAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL29219366 | 0.83 | ALDH1A1 (0.46) | KMT2AMAOAMAOBL3MBTL1KDM4E | |
| SCHEMBL18740731 | 0.83 | MAOA (0.45) | KMT2AMAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL9315070 | 0.83 | MAOA (0.45) | KMT2AMAOAMAOBL3MBTL1KDM4E | |
| SCHEMBL29518259 | 0.83 | MAOA (0.45) | KMT2AMAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL3294354 | 0.82 | KMT2A (0.50) | KMT2AMAOAMAOBL3MBTL1KDM4E | |
| SCHEMBL29219438 | 0.80 | KCNH2 (0.48) | MAOAMAOBKDM4EALDH1A1HPGD | |
| SCHEMBL14352265 | 0.80 | MAOA (0.42) | KMT2AMAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL14128989 | 0.80 | KDM4E (0.60) | KMT2AMAOAMAOBKDM4EALDH1A1 | |
| SCHEMBL397020 | 0.79 | MAOA (0.54) | KMT2AMAOAMAOBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9938269-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2018-04-10 | — | — | US | disclosed |
| CN-103958504-B | 10A type phosphodiesterase inhibitor compound | 艾伯维德国有限责任两合公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103044391-B | A kind of DPP-IV inhibitor efficiently | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2015-11-25 | — | — | CN | disclosed |
| CN-103044392-B | A kind of preparation method of efficient DPP-IV inhibitor | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO.,LTD. (CN) | 2015-10-14 | — | — | CN | disclosed |
| EP-2726479-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co KG (DE) | 2014-05-07 | — | — | EP | disclosed |
| CN-103044392-A | Preparation method of high-efficient DPP (dipeptidyl peptidase)-IV inhibitor | LIANYUNGANG RUIZHONG PHARMACEUTICAL CO LTD | 2013-04-17 | — | — | CN | disclosed |
| CN-103044391-A | High-efficient DPP (dipeptidyl peptidase)-IV inhibitor | GUANGZHOU INST BIOMED & HEALTH | 2013-04-17 | — | — | CN | disclosed |
| WO-2013000994-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-01-03 | — | — | WO | disclosed |
| US-7153865-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-7005440-B1 | Therapeutic uses of tri-aryl acid derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-02-28 | — | — | US | disclosed |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1430030-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| CN-1183113-C | Tri-aryl acid derivatives as PPAR receptor ligands | ���ĵ�˹ҩ��¹�����˾ | 2005-01-05 | — | — | CN | disclosed |
| EP-1430030-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003018561-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| CN-1356983-A | Tri-aryl acid derivatives as PPAR receptor ligands | AVENTIS PHARM PROD INC (DE) | 2002-07-03 | — | — | CN | disclosed |
| EP-1177176-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | Aventis Pharma Deutschland GmbH (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000064876-A1 | TRI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | KMT2A 4557/4885MAOA 2536/4885MAOB 1318/4885 |
| US-20180222905-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE2A, PDE4A, PDE5A | KMT2A 737/4885MAOA 27/4885MAOB 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.